Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | BLM | P54132 | 3/20 | 0.47 |
| ▸ | USP2 | O75604 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | RGS12 | O14924 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.47 |
| ▸ | THPO | P40225 | 1/20 | 0.47 |
| ▸ | CASP7 | P55210 | 1/20 | 0.47 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL158168 | 1.00 | MAPT (0.47) | MAPTCYP2C9MEN1KMT2ABLM | |
| SCHEMBL43843 | 1.00 | MAPT (0.47) | MAPTCYP2C9MEN1KMT2ABLM | |
| SCHEMBL5324038 | 0.90 | USP2 (0.47) | MAPTCYP2C9MEN1KMT2ABLM | |
| SCHEMBL5283079 | 0.90 | USP2 (0.47) | MAPTCYP2C9MEN1KMT2ABLM | |
| SCHEMBL5282915 | 0.88 | USP2 (0.46) | MAPTCYP2C9MEN1KMT2ABLM | |
| SCHEMBL2971633 | 0.88 | GRIA1 (0.47) | MAPTCYP2C9MEN1KMT2ABLM | |
| SCHEMBL2971635 | 0.88 | GRIA1 (0.47) | MAPTCYP2C9MEN1KMT2ABLM | |
| SCHEMBL23682935 | 0.86 | GRIA1 (0.46) | MAPTCYP2C9MEN1KMT2ABLM | |
| SCHEMBL13205282 | 0.85 | TSHR (0.42) | MAPTCYP2C9MEN1KMT2ABLM | |
| SCHEMBL5285947 | 0.84 | USP2 (0.50) | MAPTCYP2C9MEN1KMT2ABLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9896481-B2 | Modified mini-hepcidin peptides and methods of using thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-02-20 | — | — | US | claimed |
| US-20160022636-A1 | PHYSIOLOGICAL LIGANDS FOR GPR139 | JANSSEN PHARMACEUTICA NV (BE) | 2016-01-28 | — | — | US | claimed |
| EP-2968240-A2 | PHYSIOLOGICAL LIGANDS FOR GPR139 | Janssen Pharmaceutica, N.V. (BE) | 2016-01-20 | — | — | EP | claimed |
| US-20140336216-A1 | PHYSIOLOGICAL LIGANDS FOR GPR139 | JANSSEN PHARMACEUTICA NV (BE) | 2014-11-13 | — | — | US | claimed |
| WO-2014152917-A2 | PHYSIOLOGICAL LIGANDS FOR GPR139 | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-25 | — | — | WO | claimed |
| EP-4731268-A1 | CROSS-LINKED VESICLES WITH LOW-BOILING POINT FLUORINATED COMPOUND | Bracco Suisse SA (CH) | 2026-04-29 | — | — | EP | disclosed |
| US-20260014283-A1 | ULTRASOUND-SENSITIVE PEPTIDE PARTICLES FOR SPATIALLY RESOLVED MOLECULE DELIVERY AND METHODS OF USING THE SAME | PENN STATE RES FOUND (US) | 2026-01-15 | — | — | US | disclosed |
| EP-4637837-A1 | CATIONIC CROSS-LINKED VESICLES | Bracco Suisse SA (CH) | 2025-10-29 | — | — | EP | disclosed |
| WO-2025090926-A1 | ULTRASOUND-SENSITIVE PEPTIDE PARTICLES WITH SURFACE-BOUND GENE EDITING TOOLS FOR SPATIALLY RESOLVED MOLECULE DELIVERY | THE PENN STATE RESEARCH FOUNDATION (US) | 2025-05-01 | — | — | WO | disclosed |
| US-20250032619-A1 | MICROFLUIDIC PREPARATION OF FLUOROCARBON CROSS-LINKED VESICLES | BRACCO SUISSE SA (CH) | 2025-01-30 | — | — | US | disclosed |
| WO-2024261165-A1 | CROSS-LINKED VESICLES WITH LOW-BOILING POINT FLUORINATED COMPOUND | BRACCO SUISSE SA (CH) | 2024-12-26 | — | — | WO | disclosed |
| US-20240358640-A1 | ULTRASOUND-SENSITIVE PEPTIDE PARTICLES FOR SPATIALLY RESOLVED MOLECULE DELIVERY | THE PENN STATE RESEARCH FOUNDATION | 2024-10-31 | — | — | US | disclosed |
| US-20160022636-A1 | PHYSIOLOGICAL LIGANDS FOR GPR139 | JANSSEN PHARMACEUTICA NV (BE) | 2016-01-28 | — | — | US | disclosed |
| EP-2968240-A2 | PHYSIOLOGICAL LIGANDS FOR GPR139 | Janssen Pharmaceutica, N.V. (BE) | 2016-01-20 | — | — | EP | disclosed |
| US-20140336216-A1 | PHYSIOLOGICAL LIGANDS FOR GPR139 | JANSSEN PHARMACEUTICA NV (BE) | 2014-11-13 | — | — | US | disclosed |
| WO-2014152917-A2 | PHYSIOLOGICAL LIGANDS FOR GPR139 | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-25 | — | — | WO | disclosed |
| EP-1078002-B1 | PEPTIDE ANTIANGIOGENIC DRUGS | ABBOTT LAB (US) | 2008-05-21 | — | — | EP | disclosed |
| US-20050124548-A1 | Peptide antiangiogenic drugs | HENKIN JACK (US) | 2005-06-09 | — | — | US | disclosed |
| US-6774211-B1 | Peptide antiangiogenic drugs | ABBOTT LABORATORIES | 2004-08-10 | — | — | US | disclosed |
| US-6716963-B1 | OLIGOPEPTIDES | ABBOTT LABORATORIES | 2004-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250032619-A1 | MICROFLUIDIC PREPARATION OF FLUOROCARBON CROSS-LINKED VESICLES | EXOSC9, CHMP4B, EXOSC5 | MAPT 2507/4885CYP2C9 2809/4885MEN1 3459/4885 |
| US-20050124548-A1 | Peptide antiangiogenic drugs | VEGFA, NPPA, FLT1 | MAPT 4603/4885CYP2C9 3361/4885MEN1 646/4885 |
| US-20260014283-A1 | ULTRASOUND-SENSITIVE PEPTIDE PARTICLES FOR SPATIALLY RESOLVED MOLECULE DELIVERY AND METHODS OF USING THE SAME | HDGFL3, HDGF, HM13 | MAPT 1797/4885CYP2C9 4498/4885MEN1 2051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.